The health insurance companies involved aim to conclude discount agreements with all suitable pharmaceutical companies in accordance with Section 130c (1) of the German Social Code (SGB) for the active substance vedolizumab. The contract is concluded within the framework of the open-house biology procedure of the health insurance companies:
Individual negotiations on the content of the contract are not conducted, uniform conditions apply. The health insurance companies do not guarantee exclusivity to individual contractual partners. The contract period is a maximum of 24 months starting from 1.7.2021. The contract ends no later than 30.6.2023 for all health insurance companies involved, irrespective of the date of conclusion of the contract. All further information can be found in the participation and contract documents. In the case of patent expiry before 30 June 2023, the contract shall automatically terminate at the end of the month of the patent expiry.
It is possible to join this open house biological process at any time within the contract period.
In view of the existence of industrial property rights in respect of the active substance subject to the contract, the participation and contract documents shall be made available only to pharmaceutical companies who offer/place medicinal products on the procedural substance at issue or make it credible in relation to the TOK: to solve/place medicinal products for the substance at issue at the procedure within the contract period.
A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.
This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure designation "Open Procedure" used in the context of this announcement text in accordance with Section IV.1.1) and the specification of the award criteria in accordance with Section II.2.5) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to procurement regulations, the validity of which is not mandatory by law or award regulations.